Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Скринер
Новости
О нас

MYGN - Myriad Genetics, Inc. Последние новости | Finranks

Home

/

MYGN

M

Myriad Genetics, Inc. (MYGN)

NMS – Цена в реальном времени. Валюта: USD

4.07

-0.14 (-3.33%)

При закрытии: May 12, 2026, 4:00 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

SALT LAKE CITY, May 07, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences. The BofA Securities 2026 Health Care Conference – 1-to-1 investor meetings taking place Wednesday, May 13, 2026.

Myriad Genetics, Inc. (MYGN) Q1 2026 Earnings Call Transcript

Myriad Genetics, Inc. (MYGN) Q1 2026 Earnings Call Transcript

Myriad Genetics, Inc. (MYGN) Q1 2026 Earnings Call Transcript

Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates

Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates

Myriad Genetics (MYGN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.03 per share a year ago.

Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business

Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business

Highl ights First quarter 2026 revenue of $200.4 million grew 2% year-over-year, reflecting stable test volume and 2% year-over-year growth in average revenue per test. First quarter 2026 test volume reflects 13% and 7% test volume growth year-over-year in Cancer Care Continuum and Mental Health, respectively, offset by a 12% decline year-over-year in Prenatal Health test volume.

Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan

Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan

The latest GeneSight® Mental Health Monitor from Myriad Genetics reveals that Americans feel mental health treatment isn't designed with them in mind.

Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026

Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026

SALT LAKE CITY, April 28, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its first quarter 2026 earnings conference call at 4:30 pm ET on Tuesday, May 5, 2026. The company's quarterly earnings will be released the same day after the market closes.

Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for

Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for

Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Видео

No Data

There is no data to display

Пресс-релизы

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

SALT LAKE CITY, May 07, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences. The BofA Securities 2026 Health Care Conference – 1-to-1 investor meetings taking place Wednesday, May 13, 2026.

Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business

Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business

Highl ights First quarter 2026 revenue of $200.4 million grew 2% year-over-year, reflecting stable test volume and 2% year-over-year growth in average revenue per test. First quarter 2026 test volume reflects 13% and 7% test volume growth year-over-year in Cancer Care Continuum and Mental Health, respectively, offset by a 12% decline year-over-year in Prenatal Health test volume.

Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan

Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan

The latest GeneSight® Mental Health Monitor from Myriad Genetics reveals that Americans feel mental health treatment isn't designed with them in mind.

Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026

Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026

SALT LAKE CITY, April 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced that it will share six abstracts, including two podium presentations, at the American Association for Cancer Research (AACR) Annual Meeting 2026. "AACR is one of the premier forums for oncology research, and we are excited to share the depth of work underway across our MRD and hereditary cancer programs, including two podium presentations demonstrating the exceptional performance of Precise MRD, Myriad's tumor-informed, ultrasensitive MRD assay," said Dale Muzzey, PhD, Chief Scientific Officer, Myriad Genetics.